Isogenica licenses protein identification technology to Centocor

Isogenica of Cambridge, UK, has entered into a license agreement with US immunology company Centocor Research & Development, which grants Centocor the non-exclusive right to use Isogenica's CIS display technology for the discovery of certain therapeutic proteins.

Isogenica will receive multi-million pound initial license fees paid over the first three years of the agreement as well as ongoing license maintenance fees and milestone payments associated with the clinical development of products discovered using Isogenica's technology.

Isogenica's CIS display technology provides a novel and effective means of rapidly identifying peptides, polypeptides and antibodies that bind with high affinity and specificity to any given molecular target. The technology can also be used for enhancing the in vivo performance of peptide therapeutic and diagnostic products.

Isogenica's core technology, CIS display, can be applied to the discovery of new antibody, peptide and polypeptide drug candidates, to the discovery of high specificity diagnostic compounds and to the isolation of target validation and other research reagents, purification reagents and environmental detection reagents.

According to Dr Kevin FitzGerald, Isogenica's ceo "CIS display technology provides a powerful new approach for the discovery of compounds for therapeutic and other in vivo applications."